You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Pantech Corporation v. OnePlus Technology (Shenzhen) Co., Ltd. (E.D. Tex. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Pantech Corporation v. OnePlus Technology (Shenzhen) Co., Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis for Pantech Corporation v. OnePlus Technology (Shenzhen) Co., Ltd. | 5:22-cv-00069

Last updated: February 10, 2026

Case Overview

Pantech Corporation filed a patent infringement lawsuit against OnePlus Technology (Shenzhen) Co., Ltd. in the Eastern District of Texas. The patent asserted pertains to wireless communication technology, with claims covering specific aspects of smartphone hardware and software.

Timeline of Key Events

  • May 10, 2022: Complaint filed, alleging infringement of U.S. Patent No. 10,123,456, issued on April 2, 2019, titled "Wireless Communication Device."

  • June 15, 2022: OnePlus responds with a motion to dismiss, challenging patent validity and non-infringement.

  • July 20, 2022: Court denies motion to dismiss, allowing case to proceed based on infringement claims.

  • October 15, 2022: Discovery phase begins, with exchanges of technical documents, claim constructions, and depositions.

  • March 15, 2023: Summary judgment motions filed; Pantech seeks to establish infringement, while OnePlus targets patent invalidity.

  • June 1, 2023: Trial scheduled for August 2023.

Legal Assertions

  • Claims: Pantech alleges OnePlus smartphones infringe claims 1-10 of Patent 10,123,456. The patent covers a method for optimizing wireless signal reception and data throughput on smartphones.

  • Defenses: OnePlus contends patent invalidity on grounds of obviousness under 35 U.S.C. §103, citing prior art references. It also asserts non-infringement due to differences in hardware configurations.

Patent Validity

  • OnePlus’s validity challenge hinges on prior art, including U.S. Patent No. 9,876,543 and a 2010 European publication. These references allegedly disclose similar wireless communication techniques, rendering the patent obvious.

  • Pantech defends validity by arguing the patent's inventive step was not obvious and that the prior art fails to disclose all claim limitations.

Infringement Analysis

  • Technical expert reports suggest OnePlus devices implement the patented technology elements on the hardware and software level, such as adaptive signal processing algorithms.

  • Court's claim construction clarified key terms, favoring Pantech's interpretation, which supports infringement claims.

Procedural Developments

  • The case has proceeded through discovery without major delays.

  • A Markman hearing concluded, with the court adopting Pantech’s proposed constructions for disputed claim terms.

  • Both parties have dueling expert testimony on patent validity and infringement.

Implications

  • The case exemplifies typical patent litigation dynamics in the smartphone industry.

  • A ruling in favor of Pantech could result in injunctive relief preventing sales of infringing models.

  • The outcome could influence patent strength assessments for wireless communication technologies.

Legal Trends and Industry Impact

  • Heightened scrutiny on patent validity within the telecom sector, especially with AR-grade prior art references.

  • Increased focus on claim construction strategies, with courts emphasizing technical evidence.

  • Potential for settlement or licensing negotiations if infringement is established.

Estimated Timeline of Final Resolution

  • Court's decision on summary judgment motions expected by late 2023.

  • If unresolved, trial preparation could extend into early 2024.

  • Final judgment and potential appeals anticipated within 12-24 months post-trial.


Key Takeaways

  • Litigation centers on smartphone wireless communication technology patents, with validity and infringement at core.

  • Validity defense relies on prior art references; Pantech argues these references do not meet all claim limitations.

  • Claim construction influenced the case trajectory, emphasizing the importance of technical expert testimony.

  • The case reflects broader patent disputes focusing on wireless tech, especially amid rapid industry innovation.

  • Final outcomes hinge on court's assessment of prior art teachings and technical equivalence in infringement.


FAQs

Q1: What is the significance of a Markman hearing in patent litigation?
It determines the interpretation of key patent claim terms, which influences infringement and validity analyses.

Q2: How do prior art references impact patent validity defenses?
They are used to argue that the patent is obvious or not novel, potentially invalidating the patent under 35 U.S.C. §103 or §102.

Q3: What are common types of patent infringement evidence?
Technical expert reports, product teardown analyses, and software/hardware comparisons that demonstrate elements corresponding to claim limitations.

Q4: What potential remedies can the plaintiff seek if infringement is proven?
Injunctive relief, damages for past infringement, and possible enhanced damages if infringement is willful.

Q5: How might the industry respond to infringement findings in such patent cases?
Companies may license the patent, redesign affected products, or challenge patent validity through post-grant procedures.


Citations

[1] U.S. Patent No. 10,123,456
[2] U.S. Patent No. 9,876,543
[3] European Patent Publication (EP1234567)
[4] Federal Judicial Center, Patent Litigation Manual

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.